CONTACT US: Contact info
|
Citation |
Balasundaram MK, Singh A. Drug. Ther. Persp. 2022; 38(2): 77-83. |
|
Copyright |
(Copyright © 2022) |
|
DOI |
|
PMID |
unavailable |
|
Abstract |
Viloxazine (SPN-812), an age-old antidepressant, has recently been approved by the US FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children aged 6-17 years, at a dose range of 100-400 mg/day. Viloxazine acts primarily by norepinephrine reuptake inhibition and may also modulate the serotonergic system. The efficacy of viloxazine for the treatment of ADHD in children aged 6-17 years has been demonstrated in a series of short-term clinical trials. The most common adverse events include somnolence and gastrointestinal upset, while the FDA has issued a black-box warning regarding suicidal ideation or behavior. This article summarizes the information regarding viloxazine based on previously published narrative reviews, preclinical studies, and blinded controlled clinical trials. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG. Language: en |
|
Keywords |
adolescent; human; child; suicidal ideation; suicide attempt; suicidal behavior; amphetamine; monoamine oxidase inhibitor; paroxetine; headache; somnolence; noradrenalin; drug mechanism; gastrointestinal symptom; drug safety; drug efficacy; drug tolerability; nausea; methylphenidate; viloxazine; C peptide; drug formulation; drug therapy; atomoxetine; Article; Clinical Global Impression scale; cytochrome P450 2D6; serotonin noradrenalin reuptake inhibitor; decreased appetite; randomized controlled trial (topic); controlled clinical trial (topic); faintness; pharmacokinetics; time to maximum plasma concentration; adverse drug reaction; meta analysis (topic); systematic review (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); IC50; attention deficit hyperactivity disorder; maximum concentration; noradrenalin transporter |